Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, has completed a laboratory expansion at its active pharmaceutical ingredients (API) manufacturing site at Nansha, China. The expansion is focused on extending the capabilities and capacity of development laboratories and kilogram-scale cGMP manufacturing laboratories for clinical supply of highly-potent APIs (HPAPI). HPAPIs represent a growing part of the small molecules pipeline with special requirements r...